CANbridge Pharmaceuticals Inc.
1228.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$813.57M
Close$
Share Statistics
| Market cap | $813.57 Million |
|---|---|
| Enterprise Value | $754.27 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.03 |
| Beta | -0.09 |
| Outstanding Shares | 564,115,822 |
Return
| Return on Equity | 41.60% |
|---|---|
| Return on Assets | -42.37% |
| Return on Invested Capital | 68.39% |
Valuation & Multiples
| P/E Ratio | -10.33 |
|---|---|
| PEG | 6.35 |
| Price to Sales | - |
| Price to Book Ratio | -1.94 |
| Enterprise Value to Revenue | 13.55 |
| Enterprise Value to EBIT | -7.63 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$24.36 M
Average shareholder expectationNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About CANbridge Pharmaceuticals Inc.
39 employees
CEO: Qun Xue CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase...